Private company
Instituto Bioclon
Mexican research institute
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize Anavip becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- HeadquartersMexico City1
See how the biggest companies compare on our leaderboards
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize Anavip becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.2
Timeline
- 1990Founded Founded1
Links
- WikipediaInstituto Bioclon
- WikidataQ6041278
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataInstituto Bioclon on Wikidata
- 2WikipediaInstituto Bioclon on Wikipedia